Novavax (NVAX) Director Buys 100K Shares

Novavax (NASDAQ: NVAX) Director, Gail Bourdreaux, bought 100,000 shares on 09/20 at $1.45, bringing her stake to 200,000 shares.

Ms. Boudreaux most recently served as the Executive Vice President of UnitedHealth Group from May 2008 until February 2015 and was the Chief Executive Officer of UnitedHealthcare from January 2011 to November 2014.

Share of NVAX collapsed 77% over the last week after the company announced the Resolve trial, a Phase 3 trial of our RSV F Vaccine in 11,856 older adults (60 years of age and older), did not meet the pre-specified primary or the secondary efficacy objectives, and did not demonstrate vaccine efficacy.

You May Also Be Interested In

• Canaan Inc. (CAN) Announces Proposed Share Purchase by Management
• Nordstrom (JWN) CEO Erik Nordstrom Reports 7.45% Stake, Seeks to Finance Potential Deal with Debt/Equity
• Shah Capital nominates two directors to board of Novavax (NVAX)